The Egypt In-Vitro Fertilization (IVF) Market size was valued at USD 328.41 million in 2018 to USD 521.36 million in 2024 and is anticipated to reach USD 947.89 million by 2032, at a CAGR of 7.23% during the forecast period.
Rising infertility rates, delayed pregnancies, and lifestyle shifts are key factors driving market growth. Improved awareness of assisted reproductive technologies and advancements in treatment success rates are encouraging more patients to seek IVF services. Increasing investments in fertility clinics and the introduction of AI-enabled embryo selection systems are enhancing efficiency. Strong private sector participation and better insurance support are making IVF treatments more accessible across urban areas. Expanding medical tourism further strengthens the market outlook.
Cairo holds the largest market share due to its advanced fertility infrastructure, specialist availability, and strong patient inflow. Alexandria follows with expanding fertility service networks and clinic modernization. Upper Egypt and emerging subregions are gaining momentum through growing healthcare investments and outreach programs. It reflects a wider distribution of fertility services across the country, supported by rising awareness and infrastructure development. This regional diversification positions the market for sustainable long-term growth.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Egypt In-Vitro Fertilization (IVF) Market was valued at USD 328.41 million in 2018, reached USD 521.36 million in 2024, and is projected to hit USD 947.89 million by 2032, growing at a CAGR of 7.23%.
Cairo and Greater Cairo lead with 42.5% share due to advanced fertility infrastructure, high awareness, and strong clinic concentration. Alexandria follows with 29.6%, supported by healthcare investments, while Upper Egypt holds 27.9%, reflecting rising treatment demand.
Upper Egypt is the fastest-growing region with a 27.9% share, driven by infrastructure expansion, outreach programs, and growing accessibility in underserved areas.
Frozen non-donor IVF cycles hold the largest segment share at 38%, supported by flexible scheduling, improved success rates, and better embryo preservation technologies.
Fresh non-donor IVF cycles account for 33% of the segment share, while frozen donor and fresh donor IVF cycles represent 17% and 12% respectively, reflecting balanced growth across treatment options.
Market Drivers
Rising Infertility Rates and Changing Lifestyle Patterns Accelerating the Demand for IVF Procedures
The growing number of infertility cases drives the need for advanced reproductive treatments. Sedentary lifestyles, obesity, stress, and delayed marriages contribute to declining fertility rates. It fuels the adoption of assisted reproductive technologies across both urban and semi-urban regions. Women are seeking IVF earlier due to growing awareness of fertility timelines. Clinics offer specialized services to support personalized treatment plans. Healthcare campaigns are influencing more couples to consider IVF as a reliable option. Egypt In-Vitro Fertilization (IVF) Market benefits from evolving social attitudes toward fertility care. The trend creates strong momentum for procedure volumes and infrastructure expansion.
Government and Private Sector Investments Expanding IVF Infrastructure and Accessibility
Strong support from healthcare authorities and private investors strengthens the fertility ecosystem. Clinics receive incentives to upgrade laboratories and introduce modern reproductive technologies. It improves patient accessibility and boosts treatment capacity. Government-backed awareness programs are creating a favorable environment for service expansion. The private sector’s role in developing advanced clinics enhances regional coverage. Investments focus on high-quality embryo culture systems and automated monitoring tools. Fertility centers gain higher operational efficiency through new equipment and trained specialists. The expansion supports growing patient demand while improving treatment outcomes.
Technological Advancements Improving IVF Success Rates and Treatment Efficiency
Rapid innovation in reproductive medicine is increasing procedural accuracy and patient trust. Modern techniques like time-lapse embryo imaging and AI-powered embryo selection improve success rates. It ensures better embryo development tracking and selection. Clinics integrate digital monitoring systems to enhance care delivery. These advancements reduce procedural risks and improve pregnancy rates. Patients benefit from reduced cycle failure and higher cost efficiency. Technology adoption makes fertility care more standardized and effective. Continuous R&D ensures that clinics stay aligned with international best practices.
For instance, Madina–Endocare Fertility Center in Cairo reports IVF pregnancy success rates of up to 70% among women aged 30–35, supported by advanced reproductive technologies such as AI-assisted embryo scoring and time-lapse incubators. This positions the center among Egypt’s leading fertility facilities.
Growing Medical Tourism and Rising Awareness Enhancing Market Penetration
Egypt is attracting international patients for affordable and quality fertility care. Advanced clinic infrastructure and skilled medical professionals strengthen its reputation. It positions the country as a competitive destination in regional fertility tourism. Awareness campaigns are informing couples about available treatment options. Fertility centers provide flexible packages and multilingual support to international patients. It boosts cross-border patient flow and drives revenue growth. Positive success stories further build trust among local and foreign couples. Strong demand from regional and African patients is supporting sustainable expansion.
For example, Bedaya Hospital reports IVF success rates between 50 % and 60 % depending on patient profile, and welcomes many international patients from Africa and the Middle East for advanced fertility treatments.
Market Trends
Adoption of Digital Health Platforms and Teleconsultation Transforming Fertility Care Delivery
The integration of digital platforms improves patient engagement and treatment coordination. Clinics offer teleconsultation to simplify the initial assessment process. It reduces waiting times and enhances convenience for patients in remote regions. Fertility specialists use secure platforms to monitor treatment cycles. Patients access virtual counseling, follow-up sessions, and treatment planning. Digital integration improves operational efficiency and patient satisfaction. Egypt In-Vitro Fertilization (IVF) Market is aligning with global digital healthcare trends. This shift strengthens continuity of care and patient experience.
For instance, the Egypt Healthcare Authority launched a Virtual Hospital project in Ismailia that includes 9 telemedicine clinics and 4 tele-ICU clusters linked to the UHIS network. This initiative enhances digital healthcare access and supports virtual consultations across governorates.
Shift Toward Personalized Fertility Treatments and Tailored Protocols
Fertility clinics are adopting individualized treatment strategies based on patient profiles. Genetic testing and hormone mapping help design more accurate stimulation protocols. It leads to optimized embryo transfer and improved pregnancy outcomes. Advanced diagnostic tools enable clinics to detect specific fertility issues. Patients receive tailored plans that reduce cycle failures and treatment burden. This approach boosts clinical success rates and patient confidence. Clinics gain a competitive edge through better personalization and technology adoption. Personalized care is reshaping patient expectations and treatment standards.
Integration of AI and Automation Enhancing Procedural Accuracy and Laboratory Efficiency
Artificial intelligence supports embryo grading, timing optimization, and clinical decision-making. Automation in laboratories reduces human errors and improves consistency. It ensures precise handling of gametes and embryos. AI algorithms support embryo viability prediction, improving implantation rates. Clinics adopt automated cryostorage systems and data tracking platforms. This enhances lab workflows and maintains treatment quality. Egypt In-Vitro Fertilization (IVF) Market is leveraging these tools to enhance procedural outcomes. Technology-driven precision boosts patient trust and clinical performance.
For instance, Conceivable Life Sciences’ AURA system uses AI and robotics to automate key steps in IVF laboratory workflows. Early trials and clinical validations highlight its potential to improve standardization and efficiency in fertility treatments.
Growing Male Infertility Awareness Encouraging Comprehensive Treatment Approaches
Rising awareness of male infertility is shifting focus to inclusive fertility care. Clinics offer advanced diagnostic services and sperm selection techniques. It improves treatment planning and overall success rates. Social campaigns address stigma, encouraging more men to undergo evaluation. Healthcare providers emphasize equal participation in fertility management. Specialized procedures like ICSI are gaining wider acceptance. This evolution creates a balanced approach to fertility treatment. Changing awareness patterns drive more complete and effective patient pathways.
Market Challenges Analysis
High Cost of Fertility Treatments and Limited Insurance Coverage Restricting Patient Access
The high cost of IVF procedures remains a major barrier to wider adoption. Treatment cycles often require multiple attempts, increasing the financial burden. It limits access for middle-income and rural populations. Insurance coverage for fertility treatments is limited, creating affordability gaps. Patients face out-of-pocket expenses that discourage timely treatment. Clinics struggle to expand services in lower-income regions due to limited demand. Egypt In-Vitro Fertilization (IVF) Market faces pricing pressure as competition grows. Cost barriers slow penetration and create inequality in access.
Limited Specialized Workforce and Regulatory Complexity Slowing Market Expansion
A shortage of skilled embryologists and reproductive specialists affects service quality. Regulatory guidelines around IVF vary and create operational uncertainty. It complicates the licensing and compliance process for clinics. Delays in approvals hinder new clinic setups and expansions. Training programs for fertility professionals remain insufficient. Inconsistent oversight impacts patient confidence and procedural outcomes. Clinics must invest heavily in staff development to maintain standards. A more structured regulatory environment is essential to support sustainable growth.
Market Opportunities
Rising Public-Private Partnerships and Infrastructure Modernization Creating Expansion Scope
Collaboration between government agencies and private clinics is strengthening healthcare delivery. Fertility centers gain access to improved facilities, equipment, and funding. It supports broader treatment coverage and improved patient experience. Training initiatives create skilled professionals to meet rising demand. Egypt In-Vitro Fertilization (IVF) Market benefits from infrastructure modernization. Public-private alliances create a stable platform for long-term growth. Expanding outreach to underserved regions enhances nationwide accessibility.
Growing Demand from Regional Patients Strengthening Egypt’s Position as a Fertility Hub
Egypt is emerging as a regional hub for cost-effective and high-quality fertility services. Neighboring countries rely on Egypt’s advanced clinics for treatment. It boosts cross-border patient flow and strengthens healthcare reputation. Competitive pricing attracts patients from Africa and the Middle East. Enhanced transportation and communication networks support medical tourism. Expanding service packages create additional revenue opportunities. International patient demand reinforces Egypt’s role as a key fertility destination.
Market Segmentation Analysis
By cycle, the market is structured around four key segments: fresh non-donor IVF cycles, frozen non-donor IVF cycles, frozen donor IVF cycles, and fresh donor IVF cycles. Frozen non-donor IVF cycles dominate due to higher success rates and lower treatment risks. It supports greater scheduling flexibility and better embryo quality, which attracts more patients. Clinics are expanding cryopreservation capabilities to meet rising demand for frozen cycles. Donor cycles hold a steady share, supported by advanced matching programs and regulatory support.
For instance, Bedaya Hospital in Cairo reports IVF success rates of 50% to 60% for both fresh and frozen cycles. The clinic is known for using advanced embryo freezing and transfer techniques to improve pregnancy outcomes and support a growing international patient base.
By product, the market is segmented into equipment, reagents and media, and accessories. Reagents and media hold a significant share due to their essential role in culture and fertilization processes. It drives procurement priorities for clinics and research centers. Equipment demand is rising with the adoption of advanced monitoring systems and automated incubators. Accessories provide support for improved handling and accuracy during procedures.
For instance, Madina–Endocare IVF Center in Cairo reports IVF pregnancy success rates of up to 80% for women under 30 and 70% for women aged 30–35. The clinic uses time-lapse incubators and AI-assisted embryo selection to enhance success rates and improve procedural precision.
By type, the market includes conventional IVF, IVF with ICSI, IVF with donor eggs, and others. IVF with ICSI leads due to its effectiveness in male infertility treatment. It improves fertilization rates and strengthens treatment outcomes. Conventional IVF maintains relevance in standard cases with lower complexities.
By end-user, the market covers fertility clinics, hospitals and surgical centers, cryobanks, and research institutes. Fertility clinics dominate due to specialized infrastructure, skilled staff, and strong patient preference. It supports higher treatment volumes and faster technology integration. Hospitals and cryobanks complement this growth through supportive services and broader healthcare coverage in the Egypt In-Vitro Fertilization (IVF) Market.
Segmentation
By Cycle
Fresh Non-donor IVF Cycles
Frozen Non-donor IVF Cycles
Frozen Donor IVF Cycles
Fresh Donor IVF Cycles
By Product
Equipment
Reagents and Media
Accessories
By Type
Conventional IVF
IVF with ICSI
IVF with Donor Eggs
Others
By End-User
Fertility Clinics
Hospitals & Surgical Centers
Cryobanks
Research Institutes
Regional Analysis
Cairo and Greater Cairo Leading the Market with 42.5% Share
Cairo and the surrounding metropolitan area represent the largest subregional share in the Egypt In-Vitro Fertilization (IVF) Market with 42.5%. The dominance is driven by advanced healthcare infrastructure, a dense network of fertility clinics, and a strong concentration of specialized reproductive centers. It benefits from high awareness levels, skilled medical professionals, and better access to modern technologies. Patients prefer this region due to shorter waiting times and higher success rates. International patients also contribute to clinic revenues through medical tourism. Strong public and private investments continue to strengthen IVF infrastructure across Cairo.
Alexandria and Coastal Regions Holding 29.6% Share
Alexandria ranks second with a 29.6% market share, supported by growing fertility treatment adoption and expanding clinic capacity. It serves as a strategic hub for both local and international patients due to its developed healthcare ecosystem and proximity to major transport routes. The subregion benefits from increased investments in laboratory equipment and cryopreservation facilities. Fertility clinics are upgrading services to match the standards seen in Cairo. It supports balanced regional distribution of fertility care and reduces patient migration to the capital. Demand is rising among couples in urban and semi-urban districts surrounding Alexandria.
Upper Egypt and Other Emerging Subregions Capturing 27.9% Share
Upper Egypt and other emerging subregions together account for 27.9% of the market share. These areas are witnessing rising investments in fertility infrastructure and outreach programs. It reflects growing demand from underserved populations seeking accessible treatment options. Clinics are expanding operations through partnerships, satellite centers, and mobile care programs. Regional awareness campaigns are improving treatment acceptance rates. Lower procedural costs compared to metropolitan areas support patient inflow. The expansion of services in these subregions indicates a shift toward more inclusive national fertility care coverage.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The competitive landscape of the Egypt In-Vitro Fertilization (IVF) Market is defined by strong participation from global and regional players. Leading companies such as Thermo Fisher Scientific, Cook Medical, Vitrolife AB, Irvine Scientific, and EMD Serono focus on advanced reproductive solutions and laboratory innovations. It emphasizes high-quality reagents, precision equipment, and digital embryo monitoring platforms to strengthen clinical outcomes. Regional players like BioART Fertility Centre enhance market accessibility through localized service networks and cost-effective offerings. Cooper Surgical and OvaScience invest in product development to support personalized treatment plans. Strategic moves include mergers, acquisitions, product launches, and clinic expansions to secure competitive positions. Hospitals such as Siriraj and Ramathibodi strengthen their capabilities through partnerships with fertility technology providers. Continuous innovation, infrastructure expansion, and advanced fertility protocols define competitive differentiation, creating a dynamic and rapidly evolving landscape.
Recent Developments
In October 2025, Thermo Fisher Scientific announced a research partnership with AstraZeneca BioVentureHub to promote next-generation biotechnological innovation. Dated October 1, 2025, the collaboration aims to boost life science research capabilities relevant to IVF drug development by combining Thermo Fisher’s analytical tools and AstraZeneca’s life science applications.
In October 2025, EMD Serono, a branch of Merck KGaA, entered a strategic partnership with the U.S. government under President Donald Trump’s administration. The initiative aims to broaden affordable access to IVF therapies, delivering up to 84% discounts on drugs like Gonal-f and Ovidrel. Though U.S.-focused, this move underscores EMD Serono’s increasing role in expanding IVF accessibility globally—including regions like Africa through affiliated fertility partnerships.
In May 2025, Vitrolife AB became the lead investor in AutoIVF, a MedTech company that created OvaReady™, an automated system that enhances egg retrieval and preparation. The investment aligns with Vitrolife’s mission to improve access and affordability of IVF treatments worldwide by automating processes and scaling innovation across fertility clinics, including emerging fertility markets like Egypt.
In April 2025, CooperSurgical collaborated with The Wyatt Foundation and Conceive Fertility Foundation to launch the 2025 IVF Grant Program, which provides financial assistance to patients undergoing IVF treatments. CooperSurgical contributes preimplantation genetic testing (PGT) grants, supporting advanced fertility diagnostics globally and offering applications for clinics in emerging IVF hubs like Egypt.
Report Coverage
The research report offers an in-depth analysis based on Cycle, Product, Type and End-User. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Growing investments in fertility clinics and reproductive technology will strengthen clinical infrastructure.
Expanding digital health adoption will improve patient monitoring and personalized treatment plans.
Integration of AI and automation in laboratories will boost procedural accuracy and embryo selection.
Increasing cross-border fertility tourism will position Egypt as a key regional fertility hub.
Expanding cryopreservation capabilities will drive demand for frozen cycles and flexible treatment options.
Rising public awareness campaigns will increase early diagnosis and treatment adoption.
Regional clinic expansion will enhance service accessibility in underserved areas.
Strategic partnerships between private and public healthcare providers will accelerate technology diffusion.
Continuous training and development programs will address the shortage of skilled fertility specialists.
Strengthened regulatory frameworks will improve procedural standards and patient trust in fertility care.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: IN-VITRO FERTILIZATION (IVF) MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Country-wise Price Trend
3.6.2 Price Trend by Product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Country-wise Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Country-wise Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Cycle & Type Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Country
6.1.1. Egypt In-Vitro Fertilization (IVF) Market Import Revenue By Country
6.2. Export Analysis by Country
6.2.1. Egypt In-Vitro Fertilization (IVF) Market Export Revenue By Country CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Egypt In-Vitro Fertilization (IVF) Market: Company Market Share
7.2. Egypt In-Vitro Fertilization (IVF) Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Country-wise Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: IN-VITRO FERTILIZATION (IVF) MARKET – BY CYCLE SEGMENT ANALYSIS
8.1. In-Vitro Fertilization (IVF) Market Overview by Cycle Segment
8.1.1. In-Vitro Fertilization (IVF) Market Revenue Share By Cycle
8.2. Fresh Non-donor IVF Cycles
8.3. Frozen Non-donor IVF Cycles
8.4. Frozen Donor IVF Cycles
8.5. Fresh Donor IVF Cycle CHAPTER NO. 9: IN-VITRO FERTILIZATION (IVF) MARKET – BY PRODUCT SEGMENT ANALYSIS
9.1. In-Vitro Fertilization (IVF) Market Overview by Product Segment
9.1.1. In-Vitro Fertilization (IVF) Market Revenue Share By Product
9.2. Equipment
9.3. Reagents and Media
9.4. Accessories CHAPTER NO. 10: IN-VITRO FERTILIZATION (IVF) MARKET – BY TYPE SEGMENT ANALYSIS
10.1. In-Vitro Fertilization (IVF) Market Overview by Type Segment
10.1.1. In-Vitro Fertilization (IVF) Market Revenue Share By Type
10.2. Conventional IVF
10.3. IVF with ICSI
10.4. IVF with Donar Eggs
10.5. Others CHAPTER NO. 11: IN-VITRO FERTILIZATION (IVF) MARKET – BY END-USER SEGMENT ANALYSIS
11.1. In-Vitro Fertilization (IVF) Market Overview by End-User Segment
11.1.1. In-Vitro Fertilization (IVF) Market Revenue Share By End-User
11.2. Fertility Clinics
11.3. Hospitals & Surgical Centers
11.4. Cryobanks
11.5. Research Institutes CHAPTER NO. 12: IN-VITRO FERTILIZATION (IVF) MARKET – COUNTRY-WISE ANALYSIS
12.1. In-Vitro Fertilization (IVF) Market Overview by Country Segment
12.1.1. Egypt In-Vitro Fertilization (IVF) Market Revenue Share By Country
12.1.2. Country
12.1.3. Egypt In-Vitro Fertilization (IVF) Market Revenue By Country
12.1.4. Cycle
12.1.5. Egypt In-Vitro Fertilization (IVF) Market Revenue By Cycle
12.1.6. Product
12.1.7. Egypt In-Vitro Fertilization (IVF) Market Revenue By Product
12.1.8. Type
12.1.9. Egypt In-Vitro Fertilization (IVF) Market Revenue By Type
12.1.10. End-User
12.1.11. Egypt In-Vitro Fertilization (IVF) Market Revenue By End-User CHAPTER NO. 13: COMPANY PROFILES
13.1. Thermo Fisher Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Financial Overview
13.1.4. Recent Developments
13.1.5. Growth Strategy
13.1.6. SWOT Analysis
13.2. Cook Medical, Inc.
13.3. Vitrolife AB
13.4. Irvine Scientific
13.5. EMD Serono, Inc.
13.6. BioART Fertility Centre
13.7. Cooper Surgical
13.8. OvaScience, Inc.
13.9. Siriraj Hospital
13.10. Ramathibodi Hospital
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Egypt In-Vitro Fertilization (IVF) Market, and what is its projected size in 2032?
The Egypt In-Vitro Fertilization (IVF) Market is valued at USD 521.36 million in 2024 and is projected to reach USD 947.89 million in 2032.
At what Compound Annual Growth Rate is the Egypt In-Vitro Fertilization (IVF) Market projected to grow between 2024 and 2032?
The Egypt In-Vitro Fertilization (IVF) Market is projected to grow at a CAGR of 7.23% during the forecast period.
Which Egypt In-Vitro Fertilization (IVF) Market segment held the largest share in 2024?
The frozen non-donor IVF cycles segment held the largest share in the Egypt In-Vitro Fertilization (IVF) Market in 2024.
What are the primary factors fueling the growth of the Egypt In-Vitro Fertilization (IVF) Market?
The Egypt In-Vitro Fertilization (IVF) Market is driven by rising infertility rates, technological advancements, and growing awareness of assisted reproductive treatments.
Who are the leading companies in the Egypt In-Vitro Fertilization (IVF) Market?
Key companies in the Egypt In-Vitro Fertilization (IVF) Market include Thermo Fisher Scientific, Cook Medical, Vitrolife AB, EMD Serono, and Cooper Surgical.
Which region commanded the largest share of the Egypt In-Vitro Fertilization (IVF) Market in 2024?
Cairo and Greater Cairo commanded the largest share of the Egypt In-Vitro Fertilization (IVF) Market in 2024 due to advanced healthcare infrastructure and high treatment availability.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Latin America Retail Pharmacy Market size was valued at USD 54,202.26 million in 2018 to USD 65,793.78 million in 2024 and is anticipated to reach USD 83,665.54 million by 2032, at a CAGR of 2.84% during the forecast period.
Healthcare Simulation Market size was valued USD 3.04 billion in 2024 and is anticipated to reach USD 9.33 billion by 2032, at a CAGR of 15.04% during the forecast period.
The Degenerative Disc Disease Treatment market was valued at USD 1.8 billion in 2024 and is projected to reach USD 3.36 billion by 2032, growing at a CAGR of 8.1% during the forecast period.
Germany Compounding Pharmacies Market size was valued at USD 381.95 Million in 2018, growing to USD 535.21 Million in 2024, and is anticipated to reach USD 829.32 Million by 2032, at a CAGR of 5.24% during the forecast period.
Italy Compounding Pharmacies Market size was valued at USD 267.42 Million in 2018, growing to USD 379.23 Million in 2024, and is anticipated to reach USD 597.97 Million by 2032, at a CAGR of 5.45% during the forecast period.
Japan Compounding Pharmacies Market size was valued at USD 142.60 million in 2018 and increased to USD 221.90 million in 2024. The market is anticipated to reach USD 403.45 million by 2032, growing at a CAGR of 7.23% during the forecast period.
Glucose Biosensors Market size was valued USD 18.49 billion in 2024 and is anticipated to reach USD 28.16 billion by 2032, at a CAGR of 5.4% during the forecast period.
The UK Psychometric Assessments Services market size was valued at USD 210.20 million in 2018 and increased to USD 245.50 million in 2024. It is anticipated to reach USD 410.70 million by 2032, growing at a CAGR of 6.64% during the forecast period.
The U.S. Psychometric Assessments Services market size was valued at USD 1,856.56 million in 2018, increasing to USD 2,220.19 million in 2024, and is anticipated to reach USD 3,788.99 million by 2032, growing at a CAGR of 6.91% during the forecast period.
Glucometer market size was valued at USD 18.3 billion in 2024 and is anticipated to reach USD 46.28 billion by 2032, at a CAGR of 12.3% during the forecast period.
The Fluoroscopy Equipment market size was valued at USD 2.06 billion in 2024 and is projected to reach USD 2.37 billion by 2032, growing at a CAGR of 1.8% during the forecast period.
The Dental Impression Systems market size was valued at USD 1.87 billion in 2024 and is anticipated to reach USD 3.78 billion by 2032, growing at a CAGR of 9.2% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$2999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
